BCL2 and lymphoma: Given the possibility that prevalent nonsynonymous BCL2 mutations might be associated at points beyond 10 years with an increased lymphoma-associated death rate in patients receiving initial rituximab-containing therapy (Fig. 3B), the length of follow-up might be an important difference between the studies.